Published in Biol Blood Marrow Transplant on January 20, 2015
National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report. Biol Blood Marrow Transplant (2016) 0.79
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood (2016) 0.75
The PedsQL: measurement model for the pediatric quality of life inventory. Med Care (1999) 11.09
Population estimates of sickle cell disease in the U.S. Am J Prev Med (2010) 4.64
Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ (2005) 4.40
Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) (2005) 3.33
The cost of health care for children and adults with sickle cell disease. Am J Hematol (2009) 2.66
National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration. Health Aff (Millwood) (2013) 1.98
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood (2011) 1.90
Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol (2007) 1.84
Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol (2006) 1.61
Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer (2009) 1.54
Economics of hematopoietic cell transplantation. Blood (2012) 1.47
Health-related quality of life of pediatric patients receiving allogeneic stem cell or bone marrow transplantation: results of a longitudinal, multi-center study. Bone Marrow Transplant (2006) 1.35
Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis (2010) 1.25
Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant (2012) 1.21
Sickle cell disease-related pediatric medical expenditures in the U.S. Am J Prev Med (2010) 1.16
Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health (2007) 1.05
Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer (2010) 1.04
Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant (2002) 0.99
Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant (2007) 0.92
The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant (2010) 0.90
High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. Clin Transplant (2012) 0.89
Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant (2011) 0.85
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant (2014) 0.85
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant (2013) 0.83
Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer (2011) 0.80
Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther (2014) 0.96
Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2016) 0.79
Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Children with Sickle Cell Disease and Thalassemia: a Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes. Biol Blood Marrow Transplant (2016) 0.75
Enhanced Long-Term Brain MRI Evaluation of Children with Sickle Cell Disease Following Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2017) 0.75